HC Wainwright Reiterates “Buy” Rating for PDS Biotechnology (NASDAQ:PDSB)

PDS Biotechnology (NASDAQ:PDSB)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They currently have a $21.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 430.30% from the stock’s previous close. HC Wainwright also issued estimates for PDS Biotechnology’s FY2028 earnings at $0.33 EPS.

A number of other equities research analysts also recently issued reports on PDSB. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of PDS Biotechnology in a research note on Friday, January 12th. StockNews.com downgraded shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, March 16th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, PDS Biotechnology has an average rating of “Moderate Buy” and a consensus price target of $17.33.

PDS Biotechnology Price Performance

PDS Biotechnology stock opened at $3.96 on Wednesday. The company’s 50 day simple moving average is $5.26 and its 200-day simple moving average is $5.10. The company has a market capitalization of $123.20 million, a price-to-earnings ratio of -2.32 and a beta of 1.72. PDS Biotechnology has a 1 year low of $3.61 and a 1 year high of $10.27. The company has a debt-to-equity ratio of 0.96, a quick ratio of 6.21 and a current ratio of 6.21.

Institutional Investors Weigh In On PDS Biotechnology

Large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new stake in shares of PDS Biotechnology in the 4th quarter valued at approximately $124,000. Barclays PLC increased its position in shares of PDS Biotechnology by 681.5% in the 4th quarter. Barclays PLC now owns 38,402 shares of the company’s stock valued at $191,000 after purchasing an additional 33,488 shares during the last quarter. Northern Trust Corp increased its position in shares of PDS Biotechnology by 1.3% in the 4th quarter. Northern Trust Corp now owns 249,690 shares of the company’s stock valued at $1,241,000 after purchasing an additional 3,311 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of PDS Biotechnology by 530.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 9,046 shares of the company’s stock valued at $45,000 after purchasing an additional 7,612 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of PDS Biotechnology in the 4th quarter valued at approximately $52,000. 26.84% of the stock is owned by hedge funds and other institutional investors.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.